Abstract
Biosimilar products confront novel market authorization and post-marketing use hurdles. Existing evidence is insufficient to fully address physician and payer acceptability thresholds.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 6-7 |
| Number of pages | 2 |
| Journal | GaBI Journal |
| Volume | 4 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2015 |
Keywords
- Acceptability
- Biologicals
- Biosimilars
- Interchangeability
- Pricing
ASJC Scopus subject areas
- Pharmacy
- Drug guides
Fingerprint
Dive into the research topics of 'Biosimilars: patient and physician acceptability is the fifth hurdle to market competition'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS